article thumbnail

Omnicell Unveils Groundbreaking Robotic Compounding Technology in Winter 2022 Release

Omnicell

Dennis Wright Senior Director, Product Marketing, Omnicell For more than 15 years, IV robotics has proven efficacy in safe and efficient sterile compounding, but market adoption has been limited. Our engineering team scoured through design ideas and broke down all the compounded activities into individual tasks.

article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent in 2022. percent in 2022. Having been valued at $27.04

Packaging 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Wegovy backorder: Why it happens and what to do about it

The Checkup by Singlecare

In March 2022, the drug landed on the FDA’s list of drugs in short supply. Others have just waited or turned to a compounded version of the drug,” Dr. Jordan says. Because those drugs are not FDA approved for weight loss, like Wegovy, healthcare providers may prescribe them off-label. market throughout the rest of the year.

article thumbnail

Is Mounjaro covered by Medicaid?

The Checkup by Singlecare

Mounjaro (tirzepatide) is an injectable medication prescribed for Type 2 diabetes mellitus, which some doctors may prescribe off-label for weight loss. In 2022—the year Mounjaro hit the market—Medicaid dispersed nearly $30 million to help beneficiaries pay for it, according to KFF data. Look into compounded options (but be careful).

article thumbnail

First subject dosed in psilocybin trial for rare headache disorder

pharmaphorum

The phase 1b trial should generate results in early 2022 and is something if a departure for the use of psychedelic medicines, which are typically being tested at higher doses in carefully controlled environments and alongside psychological therapy for indications like depression and post-traumatic stress disorder (PTSD).

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. This represents a significant 83% increase in sales between 2022–2029, demonstrating a compound annual growth rate (CAGR) of 9%.

Dosage 52
article thumbnail

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

pharmaphorum

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.